Drug Development

Articles

The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.

FDA Approves Roche’s Hemophilia A Biologic and Expands Indication for Leukemia Drug

As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.

J&J and Zymeworks in Bispecific Antibody Pact Worth Nearly $1.5 Billion

The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.

Pall Debuts New Inline Diafiltration Modules for Continuous Bioprocessing

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases

Adrian Wildfire is project director, Infectious Diseases &Viral Challenge Unit, SGS Life SciencesâClinical Research.

Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states. 

Using Human Challenge Trials to Develop Flu Vaccines

Agnes Shanley is senior editor of Pharmaceutical Technology.

Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.

Making Vaccines Accessible

Amber Lowry is an associate editor at UBM plc.

This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.

Cold Chain: Delivering Vaccines to Patients

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The use of approved platform technologies can reduce the time and cost required to generate new vaccines.

Accelerating Vaccine Development and Manufacturing

ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.

ADC Targets Fail Because of Aggregation Problems

Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.

Formulation and Drug Delivery